lifestyle.celebhomes.net

Author: Thryv Therapeutics Inc.

Thryv Therapeutics to Participate in UBS, RBC Capital Markets, and Jefferies Healthcare Conferences

May 12, 2026
Thryv Therapeutics Commences Patient Dosing in Wave II Clinical Study for Long QT Syndrome and Receives FDA Fast Track Designation for THRV-1268

April 22, 2026
Thryv Therapeutics Launches Pivotal Wave II Phase 2/3 Study in Long QT Syndrome Type 2

January 13, 2026
Thryv Therapeutics Announces Positive Phase 1 Results of THRV-1268 in Obese Participants

December 19, 2025
Thryv Therapeutics Strengthens Senior Leadership Team with Appointment of Matt Killeen, PhD, as Chief Business Officer

December 2, 2025
Amy Rudolph, PhD, Joins Thryv Therapeutics’ Board of Directors to Support Portfolio Progression into Heart Failure

November 22, 2025